RONKONKOMA, N.Y., Feb. 16 /PRNewswire/ -- ProRhythm, Inc. today announced the election of Mr. Ting Pau Oei to the company’s Board of Directors.
Ting Pau Oei is a Partner of L Capital Partners SBIC, LP and leads the firm’s efforts in healthcare investments. After a 22 year career at Johnson & Johnson (J&J), Mr. Oei joined L Capital Partners in 1994, a diversified $160 million venture capital fund established in 2004. From 1992 until 2004, Mr. Oei served as Vice President at Johnson & Johnson Development Corporation (JJDC), J&J’s venture capital arm. Mr. Oei has made over 50 venture capital investments in a wide variety of emerging private and public biopharmaceutical, medical device, diagnostic and healthcare services companies and has served on the boards of directors of over 20 different venture backed companies. He is a member of the BIO’s Emerging Company Investor Forum’s Advisory Board.
Mr. Oei’s election to the ProRhythm Board of Director’s follows a $5,000,000 investment in ProRhythm by L Capital Partners.
“We are pleased to welcome Mr. Oei to ProRhythm’s Board of Directors,” said Reinhard Warnking, President and CEO of ProRhythm. “Ting Pau brings substantial strategic management experience to our organization. He will be a significant asset to ProRhythm as we develop our organization to establish ProRhythm’s HIFU ablation technology as the treatment of choice for atrial fibrillation.”
About ProRhythm
Since 1997, ProRhythm has pioneered the application of HIFU (High Intensity Focused Ultrasound) to advance the minimally invasive treatment of complex medical conditions. In recent years ProRhythm has concentrated its efforts on the development of HIFU for the treatment of atrial fibrillation (AF), a debilitating arrhythmia. AF is an uncontrollable, rapid, heartbeat that results in a significant decline in the quality of life and may lead to serious complications. Globally, in excess of 6 million people are afflicted with AF and the current treatment options are expensive, often inadequate and non-curative, as with the case of drug therapy.
ProRhythm’s HIFU Ablation System is currently under investigation in clinical trials in the United States to treat AF. ProRhythm believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by atrial fibrillation. Further information can be found at www.prorhythm.com
ProRhythm, Inc.
CONTACT: Mr. Richard Fischer, Chief Financial Officer, +1-631-981-3907,ext. 105, rfischer@prorhythm.com
Web site: http://www.prorhythm.com/
